1266728-11-3 Usage
Structure
2-methyl-5-(bromomethyl)-3-(3-methoxypropyl)phenyl bromide
Explanation
This structure describes the arrangement of atoms and functional groups in the molecule. It highlights the presence of a methyl group (CH3) at the 2nd position, a bromomethyl group (Br-CH2-) at the 5th position, and a 3-methoxypropyl group (O-CH3-CH2-CH2-) at the 3rd position on the benzene ring.
Explanation
The compound is derived from benzene, a basic aromatic hydrocarbon with a six-carbon ring and three double bonds.
Explanation
The molecule contains two bromine atoms, one as part of the bromomethyl group and the other as a substituent on the phenyl ring.
Explanation
A methoxypropyl group (O-CH3-CH2-CH2-) is attached to the benzene ring at the 3rd position.
Explanation
The compound is used in the synthesis of various organic compounds and can act as a reagent in different chemical reactions, facilitating the formation of new products.
Explanation
Due to the presence of bromine atoms, the compound should be handled carefully to avoid potential hazards. Proper safety protocols should be followed during its use and disposal to minimize risks.
Derivative of benzene
Yes
Bromine content
Two bromine atoms
Methoxypropyl group
Present
Application
Organic synthesis and as a reagent in chemical reactions
Safety precautions
Handle with caution, follow proper safety protocols for brominated compounds
Check Digit Verification of cas no
The CAS Registry Mumber 1266728-11-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,6,7,2 and 8 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1266728-11:
(9*1)+(8*2)+(7*6)+(6*6)+(5*7)+(4*2)+(3*8)+(2*1)+(1*1)=173
173 % 10 = 3
So 1266728-11-3 is a valid CAS Registry Number.
1266728-11-3Relevant articles and documents
RENIN INHIBITORS
-
Page/Page column 23-24, (2011/04/13)
Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6 -alkyl or C3-6 -cycloalkyl, wherein said C1-6 -alkyl or C3-6 -cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.
